Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Millipore Opens New Facility In Singapore
“When many of our biopharmaceutical manufacturing customers began to establish significant operations in Asia, we saw a need,” said Millipore chairman, president and chief executive officer Martin Madaus.
“When many of our biopharmaceutical manufacturing customers began to establish significant operations in Asia, we saw a need,” said Millipore chairman, president and chief executive officer Martin Madaus.
The Phase II trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of bavituximab in combination with the chemotherapy drugs carboplatin and paclitaxel in
The board will consider payment of dividends depending on future performance of the company. No dividends will be paid at this point. Commentary on the results is provided
Elinogrel has shown potential to offer clinical improvements over current anti-clotting medications in helping patients avoid heart attacks and strokes, the company said. Under terms of the
The Phase I double-blind, placebo-controlled trial enrolled 20 healthy male and female subjects in sequential, dose-escalating cohorts. Subjects received once-daily oral doses of either 90mg or 150mg of
The primary aim of the study was to determine the ability of its proprietary OvaCalc algorithm to estimate the risk of malignancy in pre and postmenopausal women who
Coartem dispersible is the result of a public-private collaboration between Novartis and the nonprofit Medicines for Malaria Venture (MMV), Novartis said. According to the company, Coartem Dispersible tablets
According to Expression Analysis, the Geneblitz unit offers molecular services to pharmaceutical companies, governmental agencies, universities and research institutes. The partnership will give Expression Analysis access to these
Through a series of cash payments and equity investments under a previously announced collaborative agreement, Vical has received $17.6 million to date of the $22.6 million total committed
Cytel said that AstraZeneca’s increased use of East also features automated data transfer between its clinical data system (CDS) and East’s trial monitoring component. By eliminating manual data